Masckauchan Daiana, Trabulsi Nora, Dubé Pierre, Aubé-Lecompte Marie-Eve, Cloutier Alexis-Simon, Mitchell Andrew, Sideris Lucas
Centre de Recherche, Hôpital Maisonneuve-Rosemont, Université de Montréal, QC, Canada.
Centre de Recherche, Hôpital Maisonneuve-Rosemont, Université de Montréal, QC, Canada.
Surg Oncol. 2019 Mar;28:69-75. doi: 10.1016/j.suronc.2018.11.006. Epub 2018 Nov 13.
Complete cytoreductive surgery (CRS) followed by hyperthermic intraperitoneal chemotherapy (HIPEC) have been proven to lengthen survival in appendiceal peritoneal carcinomatosis (PC-A). The aim of this study was to analyze survival results of this therapy in our institution over the last 10 years.
Data was retrospectively reviewed and analyzed. Treatment consisted of CRS plus HIPEC with oxaliplatin. Ronnett's histologic classification was used (peritoneal mucinous carcinomatosis (PMCA), PMCA with intermediate features (PMCA-I) and disseminated peritoneal adenomucinosis (DPAM)). Overall survival (OS) and disease-free survival (DFS) estimates were calculated using Kaplan-Meier survival curves.
109 patients with PC-A underwent laparotomy with curative intent. Of those, 92 underwent CRS plus HIPEC. Median follow-up was 42 months. The 5 and 10-year OS rates for the HIPEC group were 82.2% and 76.5%. The 5 and 10-year OS estimates for DPAM and PMCA-I subgroups were 100% and 100%, 78.1% and 72.9%, respectively. For the PMCA subgroup, the 3 and 5-year OS were 61.4% and 40.1%, respectively. The 5 and 10-year DFS estimates were 71.9% and 42.7%.
CRS plus HIPEC with oxaliplatin represent an effective therapeutic approach for PC-A. Long term OS estimates for patients treated at our institution are encouraging.
已证实，完整细胞减灭术（CRS）联合热灌注腹腔化疗（HIPEC）可延长阑尾腹膜癌（PC-A）患者的生存期。本研究旨在分析过去10年我院采用该疗法的生存结果。
对数据进行回顾性审查与分析。治疗方案为CRS联合奥沙利铂进行HIPEC。采用Ronnett组织学分类法（腹膜黏液性癌（PMCA）、具有中间特征的PMCA（PMCA-I）和播散性腹膜腺黏液瘤病（DPAM））。使用Kaplan-Meier生存曲线计算总生存期（OS）和无病生存期（DFS）。
109例PC-A患者接受了根治性剖腹手术。其中，92例接受了CRS联合HIPEC。中位随访时间为42个月。HIPEC组的5年和10年OS率分别为82.2%和76.5%。DPAM和PMCA-I亚组的5年和10年OS估计值分别为100%和100%、78.1%和72.9%。对于PMCA亚组，3年和5年OS分别为61.4%和40.1%。5年和10年DFS估计值分别为71.9%和42.7%。
CRS联合奥沙利铂进行HIPEC是治疗PC-A的有效方法。我院接受治疗患者的长期OS估计令人鼓舞。
